The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index; 21 of the 27 sources its claims cite were checked for support.
A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us?
Open accessAbstract
Review/commentary on a conformational epitope in the placental malaria vaccine antigen VAR2CSA, including implications for placental sequestration and vaccine design.
Overview
CoChat Summary
## TL;DR
This short perspective argues that VAR2CSA vaccine design for placental malaria should focus on conserved conformational epitopes, using the broadly reactive human monoclonal antibody PAM1.4 as the key example. The paper highlights evidence that PAM1.4 binds a discontinuous epitope across multiple VAR2CSA domains, but that sequence variation—especially in ID1—may limit breadth.
## Key findings
- VAR2CSA mediates *Plasmodium falciparum*–infected erythrocyte binding to CSA in the placenta and is the lead placental malaria vaccine candidate, but its high polymorphism has hindered broad immunity.
- PAM1.4 was reported to bind a highly conserved conformational epitope spanning ID1, DBL2, ID2, and DBL4; in this paper, the authors note that ID1 residues K510-R511 were absent in 24% of analyzed VAR2CSA variant sequences, and that these variants cluster in a Type 2 ID1 clade comprising about one quarter of known VAR2CSA sequences.
- In binding experiments with 7 genetically diverse full-length VAR2CSA ectodomains, PAM1.4 showed variable reactivity, with the highest binding to NF54 and the lowest to 7G8; PAM1.4 did not bind M920.
- Polyclonal IgG pooled from multigravidae bound to all 7 VAR2CSA variants, though binding was lowest to M200101, which has an atypical extra DBL7ɛ domain downstream of DBL6ɛ.
## Methods
- This is a short perspective/commentary synthesizing prior structural, sequence-conservation, and antibody-binding studies on VAR2CSA and PAM1.4.
- The authors reference prior expression and characterization of 7 genetically diverse full-length VAR2CSA ectodomains in a mammalian expression system and summarize binding profiles from those proteins.
- Main analysis: qualitative interpretation of published epitope mapping, sequence conservation, and antibody binding data to infer how conformational epitopes may shape breadth of neutralization.
## Limitations
- The paper states that whether PAM1.4 binds VAR2CSA variants exhibiting Type 2 ID1 has not been investigated.
- The paper states that no VAR2CSA antibody that binds to a fully conserved VAR2CSA epitope has been identified.
- Evident from the text: this is a perspective article rather than a primary experimental study, so its conclusions depend on previously published datasets and do not present a new systematic sample or statistical analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 PAM1.4-binding profile to genetically diverse VAR2CSA recombinants. VAR2CSA protein sequence diversity of the 7 full-length VAR2CSA ectodomain has been analysed to highlight (A) sequence identity within the 7 phylogenetically distant alleles of VAR2CSA, reported in Renn and colleagues [12], by multiple alignment of NTS-DBL6 fragments (ranged from 2,640 to 2,723 amino acids) using BioEdit version 7.0.5.3 software. (B) The structure of VAR2CSA complex with PAM1.4 (PDB:7Z12) reported in Raghavan and colleagues [11] was used to map the PAMVAC (in blue) and PRIMVAC (in red) vaccine boundaries, while VH:VL chains of PAM1:4 are highlighted in orange and green. (C) The binding level of human monoclonal IgG PAM1.4 and (D) pooled purified IgG from MG to the 7 full-length VAR2CSA (Fv2) recombinants was measured by ELISA. OD units are reported. IgG, immunoglobulin G; MG, multigravidae; OD, optical density.](https://figures.cochat.ai/paper-figures/e1fd3215468d48eabc778199681cb05b/a-conformational-epitope-in-placental-malaria-vaccine-antigen-var2csa-what-does-figure-1.jpg)
Verification
Claims the paper makes
16 Valid · 0 Not valid · 3 Not checked · 17 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recently, an in-depth characterization of this human monoclonal antibody revealed that PAM1.4 binds a highly conserved conformational epitope involving residues in the ID1, DBL2, ID2, and DBL4 domains of VAR2CSA [11].”
§ A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? > A broadly reactive monoclonal antibody to VAR2CSA
What the sources say
- Supportedcites [11] SSR Raghavan, 2022, Cryo-EM reveals the conformational epitope of human monoclonal antibody PAM1.4 broadly reacting with polymorphic malarial protein VAR2CSA, PLoS Pathog source
The Discussion identifies a conformational epitope comprising closely spaced residues from ID1, DBL2, ID2 and DBL4. The Results section on epitope conservation describes its overall sequence and structural conservation, while noting that the ID1 contact residues are conserved in 76% of variants; the claim does not assert conservation in every variant. (LLM, conf=0.91)
states an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“with residues Y958 and R959 in FCR3 DBL2 the least conserved contact residues with PAM1.4.”
§ A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? > A broadly reactive monoclonal antibody to VAR2CSA
What the sources say
- Supportedcites [11] SSR Raghavan, 2022, Cryo-EM reveals the conformational epitope of human monoclonal antibody PAM1.4 broadly reacting with polymorphic malarial protein VAR2CSA, PLoS Pathog source
The Results section, “PAM1.4 epitope conservation,” explicitly identifies Y958 and R959 in FCR3 DBL2 as the least conserved contact residues in VAR2CSA. It also states that both interact with PAM1.4. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent studies have described the molecular structure of the full-length VAR2CSA ectodomain, revealing that VAR2CSA is composed of a stable core (NTS-DBL4) with CSA-binding channel(s) and a flexible arm (DBL5-6) [8,9].”
§ A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? > VAR2CSA and the development of placental malaria vaccine
What the sources say
- Supportedcites [8] R Ma, 2021, Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA., Nat Microbiol source
The Results sections on VAR2CSA architecture and CSA binding describe a stable core, a flexible DBL5ɛ–DBL6ɛ arm, and major and potential minor CSA-binding channels in the core. The paper defines the core as DBL1X through ID3, with NTS linking DBL1X to DBL4ɛ; this is consistent with the citing sentence’s approximate NTS–DBL4 designation. (LLM, conf=0.90)
- Partly supportedcites [9] K Wang, 2021, Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding, Nat Commun sourceExperimental — accuracy not yet measured
In Results and discussion, “Cryo-EM structure of the VAR2CSA ectodomain,” the paper describes a compact core spanning ID1–DBL4 and a more separated, rod-like DBL5–DBL6 region with weak contacts. The “VAR2CSA-specific DBL elements” section proposes a CS-binding groove through the core. It does not define the stable core as NTS–DBL4 or explicitly establish DBL5–DBL6 as a flexible arm. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, ID1 residues were semiconserved with residues K510-R511 (KR) of FCR3 VAR2CSA absent from 24% of the analyzed VAR2CSA variant sequences [11].”
§ A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? > A broadly reactive monoclonal antibody to VAR2CSA
What the sources say
- Supportedcites [11] SSR Raghavan, 2022, Cryo-EM reveals the conformational epitope of human monoclonal antibody PAM1.4 broadly reacting with polymorphic malarial protein VAR2CSA, PLoS Pathog source
The Results section (‘PAM1.4 epitope conservation’) states that FCR3 VAR2CSA ID1 residues K510-R511-G512 were semi-conserved in 76% of the analyzed variants and that K510-R511 were absent from 24%. This directly supports the cited sentence. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two VAR2CSA N-terminal subunits containing the minimal CSA-binding fragment [5] have been tested in Phase I clinical trials [6,7] but did not induce strain-transcending neutralizing immunoglobulin G (IgG).”
§ A conformational epitope in placental malaria vaccine antigen VAR2CSA: What does it teach us? > VAR2CSA and the development of placental malaria vaccine
What the sources say
- Partly supportedcites [6] B Mordmuller, 2019, First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria, Clin Infect Dis sourceExperimental — accuracy not yet measured
The trial description identifies PAMVAC as a VAR2CSA ID1–ID2a subunit tested in a first-in-human phase 1 trial. The Results (Immunogenicity; page unavailable) report binding-inhibitory antibodies against FCR3 parasites and IgG binding to variants from different clades, but do not establish that the vaccine failed to induce strain-transcending *functional* IgG. This paper also tests only one of the two subunits mentioned. (LLM, conf=0.88)
- Supportedcites [7] SB Sirima, 2020, PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study, Lancet Infect Dis source
The Introduction (p. 12) identifies PRIMVAC as a VAR2CSA-derived vaccine spanning the CSA-binding DBL1x–2x region, and the study design (p. 13) describes its phase Ia/Ib trial. The Discussion (p. 28) reports that vaccine-induced antibodies inhibited adhesion by the homologous strain but not by the heterologous FCR3-CSA and 7G8-CSA strains. This paper supports the claim for PRIMVAC, one of the two candidates cited. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
21 more claims · 8 with their cited sources checked
Create a free account to see all 36 claims and every source verdict.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 6
Citations
Cites
Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I., & Marsh, K. (1998) · Nature Medicine · doi:10.1038/nm0398-358 · Cited by 645 · cited 1×
“falciparum malaria in general is often speculated to result from the acquisition and accumulation of a broad repertoire of PfEMP1 variant-specific antibodies over successive exposure to the parasites [15,16].”
BackgroundRicke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D., Riley, E. M., Theander, T. G., & Hviid, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3309 · Cited by 303
Self-citationDuffy, P. E., & Fried, M. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6620-6623.2003 · Cited by 260 · cited 1×
“However, the rapid acquisition of antibodies with CSA-binding inhibition activity in paucigravid women [17,18] supports a model where protective antibodies targeting conserved epitopes in VAR2CSA are acquired already at the first episode of PM.”
BackgroundSelf-citationNielsen, M. A., Staalsoe, T., Kurtzhals, J. A. L., Goka, B. Q., Dodoo, D., Alifrangis, M., Theander, T. G., Akanmori, B. D., & Hviid, L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3444 · Cited by 207 · cited 1×
“falciparum malaria in general is often speculated to result from the acquisition and accumulation of a broad repertoire of PfEMP1 variant-specific antibodies over successive exposure to the parasites [15,16].”
BackgroundSelf-citationClausen, T. M., Christoffersen, S., Dahlbäck, M., Langkilde, A. E., Jensen, K. E., Resende, M., Agerbæk, M. Ø., Andersen, D., Berisha, B., Ditlev, S. B., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348839 · Cited by 173 · cited 1×
“Two VAR2CSA N-terminal subunits containing the minimal CSA-binding fragment [5] have been PLOS PATHOGENS”
Background(2015) · Advances in Parasitology · doi:10.1016/bs.apar.2015.02.004 · Cited by 162 · cited 1×
“Placenta-sequestering parasites preferentially express VAR2CSA, a member of the PfEMP1 family of adhesive parasite proteins [1], which selectively binds chondroitin sulfate A (CSA) on the syncytiotrophoblasts in the placenta.”
BackgroundSelf-citationMordmüller, B., Sulyok, M., Egger-Adam, D., Resende, M., de Jongh, W. A., Jensen, M. H., Smedegaard, H. H., Ditlev, S. B., Soegaard, M., Poulsen, L., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1140 · Cited by 154 · cited 2×
“4-like strain-transcending epitopes may fail to be induced by VAR2CSA subunit immunogens (Fig 1D), as seen in humans immunized with VAR2CSA fragments who mounted limited serum functional activity against heterologous strains [6,7].”
BackgroundSirima, S. B., Richert, L., Chêne, A., Konate, A. T., Campion, C., Dechavanne, S., Semblat, J.-P., Benhamouda, N., Bahuaud, M., Loulergue, P., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30739-x · Cited by 124
Bockhorst, J., Lu, F., Janes, J. H., Keebler, J., Gamain, B., Awadalla, P., Su, X.-Z., Samudrala, R., Jojic, N., & Smith, J. D. (2007) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2007.06.007 · Cited by 117 · cited 1×
“Sequence polymorphism in VAR2CSA represents an important issue for variant selection in PM vaccine development, as many studies of var2csa genetic diversity have highlighted significant sequence variation across the gene [2,3,14].”
BackgroundBarfod, L., Bernasconi, N. L., Dahlbäck, M., Jarrossay, D., Andersen, P. H., Salanti, A., Ofori, M. F., Turner, L., Resende, M., Nielsen, M. A., et al. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05503.x · Cited by 110
Self-citationEvolutionary analysis of the most polymorphic gene family in falciparum malaria
Otto, T. D., Assefa, S. A., Böhme, U., Sanders, M. J., Kwiatkowski, D. P., Pf3k consortium, Berriman, M., & Newbold, C. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15590.1 · Cited by 90
Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA.
Ma, R., Lian, T., Huang, R., Renn, J. P., Petersen, J. D., Zimmerberg, J., Duffy, P. E., & Tolia, N. H. (2021) · Nature Microbiology · doi:10.1038/s41564-020-00858-9 · Cited by 72 · cited 3×
“Allelic variation in VAR2CSA proteins did not seem to affect this structure [8], suggesting that all or most VAR2CSA variants adopt a similar fold.”
BackgroundSelf-citationA malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection
Srinivasan, P., Baldeviano, G. C., Miura, K., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0015-7 · Cited by 65 · cited 1×
“Such observation was previously demonstrated in AMA1-RON2L complex report to indicate that improved efficacy of the complex vaccine over AMA1 alone can be obtained when AMA1 is coupled to a rhoptry neck protein 2 (RON2) peptide to improve the antibody neutralizing activity [21].”
BackgroundSelf-citationWang, K., Dagil, R., Lavstsen, T., Misra, S. K., Spliid, C. B., Wang, Y., Gustavsson, T., Sandoval, D. R., Vidal-Calvo, E. E., Choudhary, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23254-1 · Cited by 52 · cited 2×
“Recent studies have described the molecular structure of the full-length VAR2CSA ectodomain, revealing that VAR2CSA is composed of a stable core (NTS-DBL4) with CSA-binding channel(s) and a flexible arm (DBL5-6) [8,9].”
BackgroundBenavente, E. D., Oresegun, D. R., de Sessions, P. F., Walker, E. M., Roper, C., Dombrowski, J. G., de Souza, R. M., Marinho, C. R. F., Sutherland, C. J., Hibberd, M. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33767-3 · Cited by 47 · cited 1×
“Sequence polymorphism in VAR2CSA represents an important issue for variant selection in PM vaccine development, as many studies of var2csa genetic diversity have highlighted significant sequence variation across the gene [2,3,14].”
BackgroundDoritchamou, J. Y. A., Herrera, R., Aebig, J. A., Morrison, R., Nguyen, V., Reiter, K., Shimp, R. L., MacDonald, N. J., Narum, D. L., Fried, M., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw197 · Cited by 35
Self-citationDoritchamou, J. Y. A., Morrison, R., Renn, J. P., Ribeiro, J., Duan, J., Fried, M., & Duffy, P. E. (2019) · Communications Biology · doi:10.1038/s42003-019-0704-z · Cited by 31 · cited 2×
“Among the expressed VAR2CSA variants, M200101 has an additional DBL7ε domain downstream of DBL6ε [13], and the M920 (harboring the Type 2 DSM in ID1) was the least similar to the other 6 variants of full-length VAR2CSA [12].”
BackgroundSelf-citationConformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
Fedechkin, S. O., George, N. L., Nuñez Castrejon, A. M., Dillen, J. R., Kauvar, L. M., & DuBois, R. M. (2020) · Journal of Virology · doi:10.1128/jvi.01879-19 · Cited by 26 · cited 1×
“Broadly neutralizing human monoclonal antibody binding to conformational epitopes has been also described in other infectious disease pathogens such as respiratory syncytial virus (RSV) [22].”
BackgroundDoritchamou, J., Renn, J. P., Jenkins, B. J., Mahamar, A., Dicko, A., Fried, M., & Duffy, P. E. (2022) · eLife · doi:10.7554/elife.76264 · Cited by 26 · cited 1×
“Broadly neutralizing monoclonal antibodies binding to conserved VAR2CSA epitopes are likely to be common among women naturally exposed to PM parasites, as a single full-length VAR2CSA ectodomain can purify broadly neutralizing activity in antibodies from PM-resistant multigravid women [19].”
BackgroundSelf-citationRenn, J. P., Doritchamou, J. Y. A., Tentokam, B. C. N., Morrison, R. D., Cowles, M. V., Burkhardt, M., Ma, R., Mahamar, A., Attaher, O., Diarra, B. S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02787-7 · Cited by 24 · cited 3×
“We have previously expressed and characterized recombinants of 7 genetically diverse fulllength VAR2CSA ectodomains (representing major clusters of var2csa sequences) (Fig 1A), in a mammalian expression system [12].”
BackgroundMethodSelf-citationDoritchamou, J., Sabbagh, A., Jespersen, J. S., Renard, E., Salanti, A., Nielsen, M. A., Deloron, P., & Tuikue Ndam, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137695 · Cited by 22 · cited 2×
“4-binding residues KR in ID1 cluster in a clade of variants that share a distinct type 2 dimorphic sequence motif (DSM) in ID1 and constitute about a quarter of known VAR2CSA sequences [3].”
BackgroundSelf-citationRaghavan, S. S. R., Dagil, R., Lopez-Perez, M., Conrad, J., Bassi, M. R., Quintana, M. D. P., Choudhary, S., Gustavsson, T., Wang, Y., Gourdon, P., et al. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010924 · Cited by 14
Self-citationDoritchamou, J., Renn, J. P., Jenkins, B. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.07.451420 · Cited by 3
Self-citation
Cited by
Hviid, L., Jensen, A. T. R., & Deitsch, K. (2024) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2024.02.001 · Cited by 26
Self-citationThe Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum
Takashima, E., Otsuki, H., Morita, M., Ito, D., Nagaoka, H., Yuguchi, T., Hassan, I., & Tsuboi, T. (2024) · Biomolecules · doi:10.3390/biom14010100 · Cited by 27
Lopez-Perez, M., Viwami, F., Ampomah, P., Šuštić, T., Larsen, M. D., Wuhrer, M., Vidarsson, G., Ofori, M. F., Ndam, N. T., & Hviid, L. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae529 · Cited by 9
“The reasons for these deficiencies remain unclear but may include underrepresentation of functionally important and structurally complex epitopes in the vaccine immunogens [44].”
Self-citationHiding in plain sight: an epitope-based strategy for a subunit malaria vaccine
Good, M. F., & Yanow, S. K. (2023) · Trends in Parasitology · doi:10.1016/j.pt.2023.08.006 · Cited by 7
Doritchamou, J., Renn, J. P., Hviid, L., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011503
Self-citation
Metadata
- Authors
- Doritchamou, J. Y. A., Renn, J. P., Hviid, L., & Duffy, P. E.
- Affiliations
- National Institutes of Health (US)
- University of Copenhagen (DK)
- Corresponding author
- Duffy, Patrick E.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-05-25
- Volume
- 19
- Issue
- 5
- Pages
- e1011370
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC10212100
- OpenAlex
- W4378211623
- Semantic Scholar
- d245db37b610eb643a93b36f7cf1f712bd4a1e19
- Cited by
- 8
- References
- 23
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-01-29)
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Pathogens (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, public-domain)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- VAR2CSA, placental malaria, conformational epitopes, Plasmodium falciparum, variant surface antigens, chondroitin sulfate A, placental sequestration, broadly neutralizing antibodies, antigenic polymorphism, immune evasion, malaria vaccine
- MeSH terms
- Antibodies, Protozoan, Epitopes, Antigens, Protozoan, Chondroitin Sulfates, Erythrocytes, Female, Humans, Malaria, Placenta, Plasmodium falciparum, Pregnancy, Malaria, Falciparum, Malaria Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.